Dr Reddy's has teamed up with RDIF to distribute the Gamaleya National Research Institute of Epidemiology and Microbiology-developed vaccine in IndiaHyderabad-based Dr Reddy's Laboratories said it expects to roll out Russia's Sputnik V COVID-19 vaccine in India in March via emergency use authorisation (EUA). Sputnik V is undergoing Phase-3 trials in India currently which is expected to be completed by February.
After the completion of the ongoing trials, Dr Reddy's would approach the Drug Controller General of India (DCGI) for EUA, based on which the vaccine will be launched in March. "The Phase 3 trial of currently ongoing. We are dosing patients and we expect to complete the dosing as part of the Phase 3 by February. After that we expect to compile the data and submit for Emergency Use Authorisation, make the request to the DCGI with our dossier," DRL's CEO of APIs and pharmaceutical services Deepak Sapra told reporters. Sapra further stated, "And based on the approval from the DCGI, we believe that we should be in a position to launch the vaccine through a EUA in the month of March 2021 in India."